Chicago, Illinois-based CME Group Inc. (CME) is a global financial derivatives marketplace operator that runs exchanges for trading futures, options, cash, and over-the-counter products. With a market capitalization of approximately $113.8 billion, the company offers benchmark contracts across major asset classes, including interest rates, equities, foreign exchange, energy, agriculture, and metals, while providing market data and risk management solutions to institutional and individual clients worldwide.
Shares of the world’s leading derivatives marketplace have outperformed the broader market over the past year. CME has advanced 12% during this period, compared with a nearly 10.1% gain in the S&P 500 Index ($SPX). The stock has maintained its momentum in 2026, rising 17% year-to-date, while the index has gained 8.3% over the same period.
More Top Stocks Daily: Go behind Wall Street’s hottest headlines with Barchart’s Active Investor newsletter.
CME has also outperformed the broader financial services sector, as represented by the iShares U.S. Broker-Dealers & Securities Exchanges ETF (IAI), which has gained 4.2% over the past year and risen marginally year-to-date.
On Oct. 21, 2026, CME Group Inc. reported its Q3 2026 results, with revenue increasing 13% year over year to a record $1.74 billion. Adjusted diluted EPS rose 12.7% to $3.02, while adjusted net income increased 10.8% to $1.08 billion. The growth was driven by higher trading activity, with average daily volume climbing 16.3% to a third-quarter record of 29.4 million contracts. Clearing and transaction fee revenue increased 12% to $1.38 billion, while market data revenue rose 20% to a record $243 million.
During the quarter, CME Group returned nearly $1 billion to shareholders, including $524 million in share repurchases and $465 million in regular quarterly dividends. The company also highlighted progress in its cloud migration, new product launches, and record average daily capital efficiencies of $100 billion. The earnings release did not include updated full-year guidance. Following the announcement, CME shares rose 3.5% in the next trading session.
For the current fiscal year ending in December 2026, analysts expect CME’s diluted EPS to increase 10.3% to $12.35. The company has beaten consensus EPS estimates in three of the past four quarters while missing expectations in one.
Among the 19 analysts covering CME stock, the consensus rating is “Moderate Buy.” This comprises seven “Strong Buy,” three “Moderate Buy,” seven “Hold,” one “Moderate Sell,” and one “Strong Sell” recommendation.
The analyst configuration is more bullish than it was a month ago, when there were six “Strong Buy” recommendations.
On Oct. 23, 2026, Goldman Sachs analyst Alexander Blostein maintained a “Sell” rating on CME Group and raised the price target to $271 from $254.
CME’s current share price of $319.37 is above the mean price target of $317.35. However, the Street-high price target of $367 suggests an upside potential of 14.9%.
On the date of publication, Abhishek Bhuyan did not directly have a position in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.
More news from Barchart
Billionaire Mark Cuban Said ‘Chips As An Asset Class Will Be The New Crypto’ but Since He Posted It, Bitcoin Is Up 20% And Chip Stocks Are Down 24% This Insurance Stock Just Raised Its Dividend by Roughly 5% Nvidia Is Down 30%. Do You Own the Stock, or Does the Stock Own You? A $1 Billion Reason Why SKHY Stock Is in Focus Today